Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho.
Nadine TschumiBlaise LukauKatleho TlaliLipontso MotaboliMpho KaoMathebe KopoKathrin HänggiMoleboheng MokebeKlaudia NaegeleIrene AyakakaKaroline LeuzingerJennifer A BrownNiklaus Daniel LabhardtPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Nine percent of people with persistent or recurring HIV viremia ≥18 months after changing to dolutegravir-based ART had dolutegravir resistance. Detection and management of emerging dolutegravir resistance must be addressed across Africa.